AstraZeneca: Ultomiris Received Accelerated Approval in the U.S. as First and Only C5 Complement Inhibitor to Reduce Proteinuria in Adults With Primary Immunoglobulin A Nephropathy
October 22, 2026
October 22, 2026
WILMINGTON, Delaware, Oct. 22 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ULTOMIRIS(R) (ravulizumab-cwvz) received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy
21 October 2026
Based on I CAN Phase III trial results from prespecified interim analysis in which ULTOMIRIS demonstrated 43.4% reduction in pro . . .
* * *
ULTOMIRIS(R) (ravulizumab-cwvz) received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy
21 October 2026
Based on I CAN Phase III trial results from prespecified interim analysis in which ULTOMIRIS demonstrated 43.4% reduction in pro . . .